eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize natureâ€™s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	$6.195	+1.56%	946
29/09/26	$6.100	+1.67%	2,044
28/09/26	$6.000	-3.92%	8,281
25/09/26	$6.245	-1.42%	9,188
24/09/26	$6.335	-0.71%	6,481

Delayed Quote Nasdaq

More quotes

Delayed Nasdaq 18:54:05 30/09/2026 +04			5-day change	1st Jan Change
6.195 ^USD	+1.56%		-2.90%	-43.17%

09-12	EXoZymes, Inc., Q2 2026 Earnings Call, Aug 20, 2026
08-13	EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	56.62M 49.96M 47.27M 42.87M 80.38M 5.43B 81.17M 567M 219M 2.77B 213M 208M 8.93B	P/E 2024	-18.5x	P/E 2025	-9.97x
Enterprise Value	54.82M 48.38M 45.77M 41.51M 77.83M 5.26B 78.6M 549M 212M 2.69B 206M 201M 8.64B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	34.02%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	EXOZ	Delayed
CBOE	EXOZ	Real-time

09-12	EXoZymes, Inc., Q2 2026 Earnings Call, Aug 20, 2026
08-13	EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-25	EXoZymes receives $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery	CI
06-08	EXoZymes Prices $5.3 Million Offering	MT
05-14	EXoZymes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-10	Exozymes Inc - announces common stock offering - SEC filing	RE
03-31	EXoZymes, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	EXoZymes, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-05	EXoZymes Inc. Reports Detailed Downline Performance Results from Its Recently Completed 100-liter Pilot Production Run of NCT	CI
12-12	EXoZymes, Inc. Achieves 100 Scale-Up of N-Trans-Caffeoyltyramine Production Process Using Its Proprietary Exozyme-Based, Cell-Free Biomanufacturing Platform	CI
11-14	EXoZymes, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	Certain Options of eXoZymes, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2025.	CI
11-11	Certain Restricted Stock Units of eXoZymes, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2025.	CI

eXoZymes, Inc. Stock

Stocks

EXOZ

US4618741098

Biotechnology & Medical Research

Valuation: eXoZymes, Inc.

Chart: eXoZymes, Inc.

Latest news: eXoZymes, Inc.

Last Transcript: eXoZymes, Inc.

Press Releases: eXoZymes, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: eXoZymes, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

09-08	EXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT	AQ
08-21	EXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today	AQ
08-19	EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets	AQ
08-12	EXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026	AQ
07-24	EXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing	AQ

1 day	+1.56%
1 week	-2.90%
Current month	-7.95%
1 month	-7.95%
3 months	-26.51%
6 months	-15.14%
Current year	-43.17%

1 week	5.77	6.66
1 month	5.77	7.28
Current year	4.35	13.4
1 year	4.35	18.4
3 years	4.35	23.99
5 years	4.35	23.99
10 years	4.35	23.99

Manager	Title	Age	Since
Michael Heltzen CEO	Chief Executive Officer	45	01/02/2024
Paul Opgenorth CTO	Chief Tech/Sci/R&D Officer	43	01/04/2019
Tyler Korman CTO	Chief Tech/Sci/R&D Officer	47	01/04/2019

Director	Title	Age	Since
James Bowie BRD	Director/Board Member	67	01/04/2019
Chris Marlett CHM	Chairman	62	21/02/2025
Anthony DiGiandomenico BRD	Director/Board Member	60	01/04/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/09/26	Fouad Nawaz	Other	Chief Financial Officer	45,000	0.4848%
26/08/26	Michael Heltzen	Buy	Chief Executive Officer	505	0.0054%
19/08/26	Damien A. Perriman	Exercice	Executive/Senior Manager	39,224	0.4226%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXOZYMES, INC.	+1.56%	-2.90%	-57.06%	-	56.62M
WUXI APPTEC CO., LTD.	+4.16%	-0.30%	+58.96%	+94.17%	71.53B
ARGENX SE	-0.19%	+1.32%	+37.20%	+81.33%	60.12B
LONZA GROUP AG	-1.51%	+2.39%	+9.10%	+36.79%	48.85B
IQVIA HOLDINGS INC.	+0.82%	+1.05%	+42.51%	+39.61%	44.28B
REVOLUTION MEDICINES, INC.	+1.91%	+8.71%	+344.03%	+692.36%	43.83B
BEONE MEDICINES AG	+2.34%	+2.08%	+9.36%	+108.74%	41.53B
CELLTRION, INC.	-0.67%	-0.45%	+4.47%	+46.37%	30.13B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.46%	+41.54%	+22.78%	27.98B
INSMED INCORPORATED	-0.09%	-2.30%	-19.71%	+355.74%	25.25B
Average	+1.35%	+0.29%	+47.04%	+164.21%	39.36B
Weighted average by Cap.	+1.43%	+0.63%	+63.63%	+155.16%

	2024	2025
Net sales	-	-
Net income	-5.86M -5.17M -4.89M -4.44M -8.32M -562M -8.4M -58.71M -22.63M -287M -22.01M -21.53M -924M	-9.16M -8.08M -7.65M -6.94M -13M -879M -13.13M -91.74M -35.36M -449M -34.39M -33.64M -1.44B
Net Debt	-8.33M -7.35M -6.96M -6.31M -11.83M -800M -11.95M -83.46M -32.17M -408M -31.29M -30.61M -1.31B	-1.8M -1.59M -1.5M -1.36M -2.55M -172M -2.58M -17.99M -6.93M -88.01M -6.74M -6.6M -283M